会计年度:2019-06-30收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 894,569,395.35 | 315,151,495.84 | 579,417,899.51 | 64.77 |
| 合计 | 4,939,065,593.94 | 1,734,581,556.01 | 3,204,484,037.93 | 64.88 |
| 化学制剂 | 2,620,972,722.23 | 558,994,276.64 | 2,061,978,445.59 | 78.67 |
| 抗微生物药物 | 318,989,415.99 | 67,060,673.53 | 251,928,742.46 | 78.98 |
| 其他 | 306,770,940.03 | 39,957,932.68 | 266,813,007.35 | 86.97 |
| 其他(补充) | 24,320,286.54 | 13,606,696.64 | 10,713,589.90 | 44.05 |
| 其中:促性激素 | 894,569,395.35 | 315,151,495.84 | 579,417,899.51 | 64.77 |
| 其中:抗微生物药物 | 318,989,415.99 | 67,060,673.53 | 251,928,742.46 | 78.98 |
| 其中:其他 | 306,770,940.03 | 39,957,932.68 | 266,813,007.35 | 86.97 |
| 其中:消化道 | 945,389,757.68 | 101,039,991.66 | 844,349,766.02 | 89.31 |
| 其中:心脑血管 | 155,253,213.18 | 35,784,182.93 | 119,469,030.25 | 76.95 |
| 消化道 | 945,389,757.68 | 101,039,991.66 | 844,349,766.02 | 89.31 |
| 心脑血管 | 155,253,213.18 | 35,784,182.93 | 119,469,030.25 | 76.95 |
| 原料药和中间体 | 1,218,996,494.87 | 846,246,039.78 | 372,750,455.09 | 30.58 |
| 诊断试剂及设备 | 365,329,401.93 | 139,333,621.52 | 225,995,780.41 | 61.86 |
| 中药制剂 | 709,446,688.37 | 176,400,921.43 | 533,045,766.94 | 75.14 |
|
会计年度:2018-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 8,860,655,670.73 | 3,359,655,064.11 | 5,501,000,606.62 | 62.08 |
| 其他(补充) | 38,335,730.78 | 20,407,724.21 | 17,928,006.57 | 46.77 |
| 西药制剂 | 4,238,248,037.33 | 911,066,207.07 | 3,327,181,830.26 | 78.50 |
| 原料药和中间体 | 2,354,276,412.34 | 1,789,518,716.37 | 564,757,695.97 | 23.99 |
| 原料药及中间体 | 2,354,276,412.34 | 1,789,518,716.37 | 564,757,695.97 | 23.99 |
| 诊断试剂及设备 | 697,330,848.98 | 274,562,687.71 | 422,768,161.27 | 60.63 |
| 中药制剂 | 1,532,464,641.30 | 364,099,728.75 | 1,168,364,912.55 | 76.24 |
|
会计年度:2018-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 754,141,363.02 | 262,061,090.33 | 492,080,272.69 | 65.25 |
| 合计 | 4,564,703,491.43 | 1,708,438,807.43 | 2,856,264,684.00 | 62.57 |
| 抗微生物药物 | 293,628,776.73 | 57,904,672.02 | 235,724,104.71 | 80.28 |
| 其他 | 345,571,093.98 | 50,693,800.30 | 294,877,293.68 | 85.33 |
| 其他(补充) | 20,963,023.60 | 8,625,392.74 | 12,337,630.86 | 58.85 |
| 西药制剂： | -- | -- | -- | -- |
| 消化道 | 624,546,828.65 | 52,475,761.78 | 572,071,066.87 | 91.60 |
| 心脑血管 | 127,110,087.44 | 26,224,471.59 | 100,885,615.85 | 79.37 |
| 原料药和中间体 | 1,199,338,557.03 | 918,750,352.76 | 280,588,204.27 | 23.40 |
| 诊断试剂及设备 | 337,600,404.27 | 133,484,911.80 | 204,115,492.47 | 60.46 |
| 中药制剂 | 861,803,356.71 | 198,218,354.11 | 663,585,002.60 | 77.00 |
|
会计年度:2017-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 西药制剂 | 3,702,112,863.13 | 751,976,319.64 | 2,950,136,543.49 | 79.69 |
| 原料药及中间体 | 2,102,959,009.12 | 1,607,443,270.68 | 495,515,738.44 | 23.56 |
| 诊断试剂及设备 | 635,721,525.53 | 265,741,530.66 | 369,979,994.87 | 58.20 |
| 中药制剂 | 2,045,244,765.20 | 430,235,760.29 | 1,615,009,004.91 | 78.96 |
|
会计年度:2017-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 664,749,567.19 | 229,462,274.69 | 435,287,292.50 | 65.48 |
| 抗微生物药物 | 228,064,619.25 | 50,390,724.11 | 177,673,895.14 | 77.90 |
| 其他 | 402,514,212.81 | 43,146,858.90 | 359,367,353.91 | 89.28 |
| 西药制剂： | -- | -- | -- | -- |
| 消化道 | 483,205,958.80 | 40,002,353.14 | 443,203,605.66 | 91.72 |
| 心脑血管 | 100,146,727.09 | 21,595,872.19 | 78,550,854.90 | 78.44 |
| 原料药和中间体 | 1,003,680,176.64 | 757,111,582.22 | 246,568,594.42 | 24.57 |
| 诊断试剂及设备 | 288,802,370.79 | 125,343,287.98 | 163,459,082.81 | 56.60 |
| 中药制剂 | 1,084,258,734.17 | 224,934,891.52 | 859,323,842.65 | 79.25 |
|
2/9 转到 
